Reference : Consultations in molecular diagnostics - A case of FIP1L1-PDGFRA-positive chronic eos...
Scientific journals : Article
Human health sciences : Hematology
Human health sciences : Oncology
Consultations in molecular diagnostics - A case of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia with a rare FIP1L1 breakpoint
Lambert, Frédéric mailto [Centre Hospitalier Universitaire de Liège - CHU > > Génétique >]
Heimann, Pierre [> > > >]
Herens, Christian mailto [Centre Hospitalier Universitaire de Liège - CHU > > PLAN COS >]
Chariot, Alain mailto [Université de Liège - ULiège > Département de pharmacie > Chimie médicale >]
Bours, Vincent mailto [Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Génétique générale et humaine]
Journal of Molecular Diagnostics
Amer Soc Investigative Pathology, Inc
Yes (verified by ORBi)
[en] The idiopathic hypereosinophilic syndrome (HES) has remained for a long time a diagnosis of exclusion. Differential diagnosis between the HES and the related chronic eosinophilic leukemia (CEL) relied on the identification of signs of clonality that allowed, when present, the reclassification of patients as CEL. Recently, a new acquired mutation was described in approximately 50% of the HES/CEL patients: a cryptic deletion on chromosome band 4q12 generating a FIP1IL1-PDGFRA fusion gene. According to the World Health Organization classification, this clonal abnormality has been proposed as a new surrogate marker for chronic eosinophilic leukemia diagnosis. Fluorescence in situ hybridization and reverse transcriptase-polymerase chain reaction protocols were developed for an accurate del(4)(q12q12) and FIP1L1-PDGFRA fusion gene detection. Here, we report a patient with a rare FIP1L1 intron 16 breakpoint located outside of the reported FIP1L1 breakpoint region (ie, from FIP1L1 introns 9 to 13). This case illustrates the risk of false-negative results with diagnostic procedures that do not take into account the occurrence of rare FIP1L1 breakpoints. As targeted therapy with tyrosine kinase inhibitors has dramatically changed the prognosis of FIP1L1-PDGFRA (+) CEL, false-negative results could hamper accurate diagnosis and treatment.
Giga-Signal Transduction
Fonds de la Recherche Scientifique (Communauté française de Belgique) - FNRS, TELEVIE, FBC, CHU, ARC ULG
Researchers ; Professionals ; Students

File(s) associated to this reference

Fulltext file(s):

Open access
Paper by F. Lambert et al. J. Mol. Diagnos 2007.pdfPublisher postprint660.35 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.